1. Home
  2. ATLO vs MGNX Comparison

ATLO vs MGNX Comparison

Compare ATLO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ames National Corporation

ATLO

Ames National Corporation

HOLD

Current Price

$31.94

Market Cap

269.2M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.12

Market Cap

256.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATLO
MGNX
Founded
1903
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.2M
256.8M
IPO Year
2001
2013

Fundamental Metrics

Financial Performance
Metric
ATLO
MGNX
Price
$31.94
$4.12
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
26.2K
646.7K
Earning Date
04-24-2026
05-08-2026
Dividend Yield
3.43%
N/A
EPS Growth
8.03
N/A
EPS
0.38
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
$83.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.96
$1.30
52 Week High
$32.16
$5.08

Technical Indicators

Market Signals
Indicator
ATLO
MGNX
Relative Strength Index (RSI) 69.84 51.17
Support Level $28.55 $3.81
Resistance Level $32.16 $4.58
Average True Range (ATR) 0.71 0.21
MACD 0.11 0.03
Stochastic Oscillator 91.97 71.52

Price Performance

Historical Comparison
ATLO
MGNX

About ATLO Ames National Corporation

Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: